How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study.

The combined evaluation of hemoglobin, CRP, and FC in at least one time point and their incorporation into risk matrices seems to be the optimal strategy for CD management, as data from additional visits did not meaningfully influence the predictions and may delay decision-making.